Cassava Sciences Files 8-K/A Amendment
Ticker: FLNA · Form: 8-K/A · Filed: Aug 9, 2024 · CIK: 1069530
| Field | Detail |
|---|---|
| Company | Cassava Sciences INC (FLNA) |
| Form Type | 8-K/A |
| Filed Date | Aug 9, 2024 |
| Risk Level | medium |
| Pages | 2 |
| Reading Time | 3 min |
| Key Dollar Amounts | $0.001 |
| Sentiment | neutral |
Sentiment: neutral
Topics: amendment, financial-condition, operations
Related Tickers: SAVA
TL;DR
Cassava Sciences just amended its 8-K filing - check for updated financial info.
AI Summary
Cassava Sciences, Inc. filed an 8-K/A amendment on August 9, 2024, related to its results of operations and financial condition as of August 8, 2024. This filing is an amendment to a previous report, indicating updates or corrections to previously disclosed information. The company, previously known as Pain Therapeutics Inc., is incorporated in Delaware and headquartered in Austin, Texas.
Why It Matters
This amendment signifies a formal update to Cassava Sciences' financial reporting, which could contain revised operational results or financial condition details that investors should be aware of.
Risk Assessment
Risk Level: medium — Amendments to SEC filings can indicate changes or corrections to previously reported information, requiring careful review by investors.
Key Numbers
- 001-41905 — SEC File Number (Identifies the company's filing history with the SEC.)
- 91-1911336 — IRS Employer Identification Number (Company's tax identification number.)
Key Players & Entities
- Cassava Sciences, Inc. (company) — Registrant
- Pain Therapeutics Inc. (company) — Former company name
- August 8, 2024 (date) — Date of earliest event reported
- August 9, 2024 (date) — Filing date
- Delaware (jurisdiction) — State of incorporation
- Austin, Texas (location) — Principal executive offices
FAQ
What specific information is being amended in this 8-K/A filing?
The filing is an amendment to a previous report concerning 'Results of Operations and Financial Condition' as of August 8, 2024. The specific details of the amendment are not provided in the header information.
When was the original event reported that this 8-K/A amends?
The date of the earliest event reported is August 8, 2024.
What is Cassava Sciences, Inc.'s former company name?
Cassava Sciences, Inc.'s former company name was PAIN THERAPEUTICS INC.
Where are Cassava Sciences, Inc.'s principal executive offices located?
The principal executive offices are located at 6801 N Capital of Texas Highway, Building 1; Suite 300, Austin, Texas 78731.
What is the SEC file number for Cassava Sciences, Inc.?
The SEC file number for Cassava Sciences, Inc. is 001-41905.
Filing Stats: 657 words · 3 min read · ~2 pages · Grade level 10.6 · Accepted 2024-08-09 08:23:15
Key Financial Figures
- $0.001 — ge on which registered Common Stock , $0.001 par value SAVA Nasdaq Capital Market
Filing Documents
- sava20240809_8ka.htm (8-K/A) — 26KB
- 0001437749-24-025654.txt ( ) — 162KB
- sava-20240808.xsd (EX-101.SCH) — 3KB
- sava-20240808_def.xml (EX-101.DEF) — 12KB
- sava-20240808_lab.xml (EX-101.LAB) — 16KB
- sava-20240808_pre.xml (EX-101.PRE) — 12KB
- sava20240809_8ka_htm.xml (XML) — 3KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On August 8, 2024, the Company issued a press release announcing financial results for the quarter ended June 30, 2024 (the "Earnings Release"). Within the financial tables included in the Earnings Release, the Company incorrectly presented Net income (loss) per share, diluted for the Six months ended June 30, 2024 as $(1.72). The Company is filing this Amendment to provide the corrected Net income (loss) per share, diluted for the Six months ended June 30, 2024 of $(0.28), which was correctly presented in the Company's quarterly report on Form 10-Q for the quarter ended June 30, 2024 filed with the Securities and Exchange Commission on August 8, 2024. The information provided in this Amendment is being furnished and shall not be deemed "filed" for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that Section. Such information shall not be incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any incorporation by reference language in such filing. SIGNATURE Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized. CASSAVA SCIENCES, INC. Date: August 9, 2024 By: /s/ Eric J. Schoen Eric J. Schoen Chief Financial Officer